207 related articles for article (PubMed ID: 36004351)
1. Case report: Early-onset osteoporosis in a patient carrying a novel heterozygous variant of the
Campopiano MC; Fogli A; Michelucci A; Mazoni L; Longo A; Borsari S; Pardi E; Benelli E; Sardella C; Pierotti L; Dinoi E; Marcocci C; Cetani F
Front Endocrinol (Lausanne); 2022; 13():918682. PubMed ID: 36004351
[TBL] [Abstract][Full Text] [Related]
2. Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations.
Palomo T; Al-Jallad H; Moffatt P; Glorieux FH; Lentle B; Roschger P; Klaushofer K; Rauch F
Bone; 2014 Oct; 67():63-70. PubMed ID: 25010833
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis related to WNT1 variants: a not infrequent cause of osteoporosis.
Peris P; Monegal A; Mäkitie RE; Guañabens N; González-Roca E
Osteoporos Int; 2023 Feb; 34(2):405-411. PubMed ID: 36396825
[TBL] [Abstract][Full Text] [Related]
5. Novel mutation in a family with WNT1-related osteoporosis.
Panigrahi I; Didel S; Kirpal H; Bellampalli R; Miyanath S; Mullapudi N; Rao S
Eur J Med Genet; 2018 Jul; 61(7):369-371. PubMed ID: 29481978
[TBL] [Abstract][Full Text] [Related]
6. Mutations in WNT1 cause different forms of bone fragility.
Keupp K; Beleggia F; Kayserili H; Barnes AM; Steiner M; Semler O; Fischer B; Yigit G; Janda CY; Becker J; Breer S; Altunoglu U; Grünhagen J; Krawitz P; Hecht J; Schinke T; Makareeva E; Lausch E; Cankaya T; Caparrós-Martín JA; Lapunzina P; Temtamy S; Aglan M; Zabel B; Eysel P; Koerber F; Leikin S; Garcia KC; Netzer C; Schönau E; Ruiz-Perez VL; Mundlos S; Amling M; Kornak U; Marini J; Wollnik B
Am J Hum Genet; 2013 Apr; 92(4):565-74. PubMed ID: 23499309
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report.
Kaneuchi Y; Iwabuchi M; Hakozaki M; Yamada H; Konno SI
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676643
[TBL] [Abstract][Full Text] [Related]
8. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
9. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
10. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause.
Campos-Obando N; Oei L; Hoefsloot LH; Kiewiet RM; Klaver CC; Simon ME; Zillikens MC
J Clin Endocrinol Metab; 2014 Apr; 99(4):1107-11. PubMed ID: 24423337
[TBL] [Abstract][Full Text] [Related]
11. Preoperative bone health assessment and optimization in spine surgery.
Anderson PA; Kadri A; Hare KJ; Binkley N
Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
[TBL] [Abstract][Full Text] [Related]
12. Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis.
Mana DL; Zanchetta MB; Zanchetta JR
Osteoporos Int; 2017 Apr; 28(4):1491-1494. PubMed ID: 27966106
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
14. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Characteristics of WNT1 Osteoporosis in Children and Young Adults.
Mäkitie RE; Haanpää M; Valta H; Pekkinen M; Laine CM; Lehesjoki AE; Schalin-Jäntti C; Mäkitie O
J Bone Miner Res; 2016 Sep; 31(9):1734-42. PubMed ID: 27005318
[TBL] [Abstract][Full Text] [Related]
16. Severe osteoporosis with multiple spontaneous vertebral fractures in a young male carrying triple polymorphisms in the vitamin D receptor, collagen type 1, and low-density lipoprotein receptor-related peptide 5 genes.
Yavropoulou MP; Kollia P; Chatzidimitriou D; Samara S; Skoura L; Yovos JG
Hormones (Athens); 2016 Oct; 15(4):551-556. PubMed ID: 28222408
[TBL] [Abstract][Full Text] [Related]
17. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
18. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
[TBL] [Abstract][Full Text] [Related]
20. Early-Onset Osteoporosis.
Mäkitie O; Zillikens MC
Calcif Tissue Int; 2022 May; 110(5):546-561. PubMed ID: 34236445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
